Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444423 | 1.00 | AR (0.44) | ARHSD17B3ESR2NR1I2ALDH1A1 | |
| SCHEMBL10088537 | 0.81 | AR (0.45) | AR | |
| SCHEMBL1914296 | 0.81 | GABRA1 (0.36) | ARPGR | |
| SCHEMBL1762439 | 0.80 | GAA (0.47) | ARALDH1A1HSD17B10PGRKIF11 | |
| SCHEMBL28344889 | 0.76 | AR (0.41) | ARPGR | |
| SCHEMBL3347622 | 0.75 | FFAR1 (0.40) | ARALDH1A1CYP2C9HSD17B10 | |
| SCHEMBL17672783 | 0.75 | NOTUM (0.52) | ARALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL21839795 | 0.74 | AR (0.40) | ARPGR | |
| SCHEMBL20536435 | 0.74 | HSD17B10 (0.43) | ARESR2ALDH1A1CYP2C9HSD17B10 | |
| SCHEMBL30444035 | 0.74 | HSD17B10 (0.43) | ARESR2ALDH1A1CYP2C9HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| CN-110678450-B | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2023-06-20 | — | — | CN | disclosed |
| EP-3612520-B1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMA (KR) | 2021-11-10 | — | — | EP | disclosed |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2021-06-24 | — | — | US | disclosed |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2020-04-16 | — | — | US | disclosed |
| EP-3612520-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | Il Dong Pharmaceutical Co., Ltd. (KR) | 2020-02-26 | — | — | EP | disclosed |
| CN-110678450-A | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018190643-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | AR 478/4885HSD17B3 153/4885ESR2 343/4885 |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | AR 149/4885HSD17B3 82/4885ESR2 220/4885 |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | AR 478/4885HSD17B3 153/4885ESR2 343/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | AR 194/4885HSD17B3 71/4885ESR2 234/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | AR 149/4885HSD17B3 82/4885ESR2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.